Source: CureToday articles
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Recent Content
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
- Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
- Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
- Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
- Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
- Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
- The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
- What Does Multiple Myeloma Mean?
- FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma